Press Releases | VETS

Torchbearer Ball 2025 Gala - Nov. 15th 2025 - Learn More ›

Beyond the One Dose Wonder: Why Psychedelic Clinical Trial Protocols Must Evolve Beyond Academic Norms

When most people hear about psychedelic clinical trials, they envision a single, transformative session, maybe two, resulting in rapid, life-changing outcomes. But the reality is more complex.

Veterans Exploring Treatment Solutions (VETS) Takes Center Stage at Psychedelic Science 2025

Veterans Exploring Treatment Solutions (VETS) brought its mission to the forefront at Psychedelic Science 2025, spotlighting the urgent need for access, equity, and innovation in veteran mental health. From policy advocacy to powerful storytelling, VETS delivered a bold message: healing is a right—and veterans deserve the freedom to pursue it.

Press Release: VETS Co-Founder & CEO Amber Capone Named to Inc.'s 2025 Female Founders 500 List

Amber Capone, Co-Founder and CEO of VETS, has been named to Inc.'s 2025 Female Founders 500 List. This recognition highlights her significant contributions and leadership in her field.

Press Release: Veterans Exploring Treatment Solutions (VETS) Leads Legislative Day of Action on March 18, 2025 in Support of Texas Ibogaine Initiative

The Legislative Day of Action aims to educate legislators on the transformative potential of ibogaine-assisted therapy for veterans struggling with OUD, co-occurring SUD, and neurological or mental health conditions, as well as address the critical issue that service members must travel internationally to access these treatments.

Press Release: Texas Lawmaker Rep. Cody Harris Introduces Bill to Fund Ibogaine Research for Addiction and Mental Health Treatment

HB 3717, introduced by Rep. Cody Harris and supported by VETS and the Texas Ibogaine Initiative, will fund FDA-approved clinical trials of ibogaine-a potential breakthrough treatment for substance use disorder and other mental health conditions affecting veterans and non-veterans.

1
2
3
6